(Q38530211)

3 September 2017

1 reference

title

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. (English)

1 reference

3 September 2017

1 reference

J A Gutierrez

1

1 reference

PubMed ID

26083155

3 September 2017

E J Lawitz

series ordinal

2

1 reference

PubMed ID

26083155

3 September 2017

F Poordad

series ordinal

3

1 reference

3 September 2017

17 June 2015

1 reference

Journal of Viral Hepatitis

3 September 2017

1 reference

3 September 2017

22

1 reference

3 September 2017

11

1 reference

3 September 2017

861-870

1 reference

Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.

3 September 2017

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

21 January 2018

1 reference

Novel therapies for hepatitis C: insights from the structure of the virus

21 January 2018

1 reference

NS5A inhibitors in the treatment of hepatitis C.

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

21 January 2018

1 reference

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

21 January 2018

1 reference

Structural biology of hepatitis C virus

21 January 2018

1 reference

New therapeutic strategies in HCV: polymerase inhibitors

21 January 2018

1 reference

Hepatitis C variability, patterns of resistance, and impact on therapy

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

Response-guided and -unguided treatment of chronic hepatitis C.

21 January 2018

1 reference

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

21 January 2018

1 reference

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

21 January 2018

1 reference

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?

21 January 2018

1 reference

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

21 January 2018

1 reference

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

21 January 2018

1 reference

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up

21 January 2018

1 reference

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

21 January 2018

1 reference

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

21 January 2018

1 reference

An interferon-free antiviral regimen for HCV after liver transplantation

21 January 2018

1 reference

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12422

1 reference

3 September 2017

1 reference

PubMed ID

26083155